Lung cancer discovered through fluid around the lung

Patient Info: Anonymized, Male, 40s

He left the hospital before the planned cancer workup and treatment could be completed.

PubMed CentralRead more →

ALK-positive inflammatory myofibroblastic lung tumor: surgery and 2-year recurrence-free surveillance

Patient Info: Anonymized, Female, 60s

Biomarkers: ALK-1-positive; TPM4-ALK rearrangement; TP53 missense variant VAF 2.3%; DNMT3A frameshift mutation VAF 2.3%

She remained stable without recurrence for 2 years after complete surgical resection of an ALK-positive inflammatory myofibroblastic tumor of the lung.

PubMed CentralRead more →

KRAS G12C Stage IV lung adenocarcinoma with synchronous urothelial carcinoma and durable response

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: Lung adenocarcinoma: KRAS ; PD-L1 TPS 5%. Urothelial carcinoma: GATA3-positive; CK7-positive; TTF1-negative.

Metastatic Site: homolateral pulmonary metastases and N2 lymph nodes…

After enfortumab vedotin, the urothelial carcinoma reached complete radiologic response and the lung cancer remained partially responding/stable; treatment was stopped after 16 months, and PET 2 months later showed complete metabolic response.

PubMed CentralRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Jennifer's Patient Story

Patient Info: Jennifer, Female | Stage IV

Biomarkers: EGFR genomic mutation

Metastatic Site: Not reported

Jennifer is alive more than 5.5 years after a Stage IV adenocarcinoma diagnosis, continuing EGFR-targeted treatment and living with ongoing side effects and surveillance needs.

The Patient StoryRead more →

Stage IV EGFR-mutated lung adenocarcinoma with suspected myocardial metastasis responding to afatinib plus chemotherapy

Patient Info: Anonymized, Male | Stage IV

Biomarkers: EGFR L861Q; PD-L1 TPS/CPS 65%. TP53, MET and PIK3CA alterations also reported.

Metastatic Site: left ventricular myocardium; mediastinal lymph nodes…

As of December 2025, the suspected left-ventricular myocardial metastasis had shrunk after 2 courses of afatinib plus pemetrexed/cisplatin, and the patient had no cardiovascular events during monitoring.

PubMed CentralRead more →

Stage IV METex14 lung adenocarcinoma: responding well to capmatinib and SBRT

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: MET exon 14 skipping mutation; PD-L1 >80%. EGFR/RAS/MEK wild type; lung-origin markers present.

Metastatic Site: brain; bone (thoracic/lumbar vertebrae, right iliac…

At 24 months after diagnosis, he was alive, asymptomatic, and continuing capmatinib with no evidence of progression and excellent tolerance.

PubMed CentralRead more →

Lung cancer mimic: allergic bronchopulmonary aspergillosis with high CEA responding to prednisolone

Patient Info: Anonymized, Female, Under 40

Biomarkers: No cancer biomarkers. CEA was high at presentation and normalized after ABPA treatment; IgE/eosinophils and Aspergillus testing supported ABPA.

As of December 2025, the lung cancer concern had been ruled out by biopsy, and ABPA symptoms, CEA, eosinophilia, and CT abnormalities improved after prednisolone.

PubMed CentralRead more →

Stage IVA EGFR-mutated lung adenocarcinoma with malignant pleural effusion: stable disease on ivonescimab plus pemetrexed

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: EGFR exon 19 deletion persisted. Later pleural fluid had PD-L1 TPS 40% / CPS 41, low TMB

Metastatic Site: pleura / malignant pleural effusion

As of August 2025, Stage IVA EGFR-mutated lung adenocarcinoma with malignant pleural effusion was stable on ivonescimab plus pemetrexed after prior progression on gefitinib, almonertinib, and ivonescimab monotherapy.

PubMed CentralRead more →

Lung adenocarcinoma with marked eosinophilia and Löffler endocarditis: clinical deterioration after treatment withdrawal

Patient Info: Anonymized, Male, 70+

Biomarkers: Markers supported lung adenocarcinoma with TTF-1 and Napsin-A positivity. Ki-67 ~30%; FGFR1 rearrangement not detected.

The patient deteriorated with severe eosinophilia, Löffler endocarditis, lung adenocarcinoma, bilateral pleural effusions, pneumonia, unstable oxygen saturation, and progressive hypotension; his family twice chose voluntary discharge or withdrawal of care.

PubMed CentralRead more →

Lung Cancer: Regina's Survivor Story

Patient Info: Regina, Female, 40s

Regina reported being cancer-free after surgical removal of a rare neuroendocrine lung tumor, while living with reduced lung capacity, survivor guilt, fear of recurrence, and medical PTSD.

The Patient StoryRead more →

Small-cell lung cancer mistaken for pulmonary embolism

Patient Info: Anonymized, Female, 60s

Biomarkers: CEA 29.84 ng/mL; NSE 26 ng/mL; TTF-1-positive; chromogranin A-positive; synaptophysin-positive; NSE-positive; Ki-67 about 70%

The patient was diagnosed with small-cell neuroendocrine carcinoma of the lung with pulmonary artery tumor embolism after persistent defects despite anticoagulation. Chemoradiotherapy was recommended but declined, and no further follow-up was available.

PubMed CentralRead more →

Stage IV NSCLC with brain metastasis and organic psychosis: improvement with blonanserin patch

Patient Info: Anonymized, Male | Stage IV

Metastatic Site: brain, bone

As of December 2025, he was living with Stage IV NSCLC and brain metastases; severe organic psychosis linked to brain metastasis improved with blonanserin transdermal patch, allowing discharge on hospital day 53.

PubMed CentralRead more →

Extensive-stage small-cell lung cancer with bone metastases: stable response after durvalumab rechallenge

Patient Info: Anonymized, Female, 60s | Stage IV

Metastatic Site: bone (axial skeleton and skull)

As of November 2025, the patient continued durvalumab with no recurrent gastritis symptoms, continued response to treatment, and no evidence of disease progression on regular CT and bone-scan surveillance.

PubMed CentralRead more →

Stage IVB EGFR L861R lung adenocarcinoma treated with afatinib, osimertinib, and chemotherapy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: EGFR L861R mutation; CEA 5.5 ng/mL; CYFRA 21-1 5.1 ng/mL

Metastatic Site: lymph nodes, lung, bone

As of September 2025, the patient remained alive 27 months after diagnosis after multiple EGFR-targeted and chemotherapy lines.

PubMed CentralRead more →

Stage IIIA KRAS/STK11/TP53-mutated lung adenocarcinoma: fatal pembrolizumab-induced myocarditis after adjuvant therapy

Patient Info: Anonymized, Male, 70+ | Stage III

Biomarkers: Ki-67 20-25%; PD-L1 expression 10%; KRAS exon 2 mutation; STK11 mutation; TP53 mutation

As of December 2025, he had died after 15 days of hospitalization from sepsis and multi-organ failure following severe pembrolizumab-induced myocarditis after adjuvant treatment for resected Stage IIIA lung adenocarcinoma.

PubMed CentralRead more →

Stage IV squamous lung cancer: complete response followed by fatal bone marrow metastasis

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: with PD-L1 95%. SCC antigen/CYFRA rose at relapse.

Metastatic Site: bone (spine, bilateral humerus, bilateral femur); bone…

As of December 2025, he had died of aspiration pneumonia 1 month after admission for biopsy-confirmed bone marrow metastasis from squamous lung cancer, despite a prior complete response to chemoimmunotherapy and pembrolizumab maintenance.

PubMed CentralRead more →

Stage IV NSCLC with brain and leptomeningeal metastases responding to radiotherapy, camrelizumab, GM-CSF, and chemotherapy

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: Lung cancer markers supported adenocarcinoma. PD-L1 negative; no common lung driver found; TMB high; MSI not detected.

Metastatic Site: brain, leptomeningeal disease, left supraclavicular…

As of March 2025, leptomeningeal metastases had complete response, brain lesions had further regression, the lung lesion had decreased from 76 mm to 21 mm, and overall disease remained in partial response with 69 months of progression-free survival since radiotherapy.

PubMed CentralRead more →

Small cell lung cancer with anti-SOX1 paraneoplastic limbic encephalitis: fatal autopsy case

Patient Info: Anonymized, Male, 60s

Biomarkers: SCLC with strong anti-SOX1 antibody, ProGRP elevation, neuroendocrine markers positive

As of November 2025, this fatal case ended on hospital day 115 after anti-SOX1 paraneoplastic limbic encephalitis associated with right hilar small cell lung cancer; autopsy confirmed SCLC and severe limbic nervous-system injury.

PubMed CentralRead more →

Stage IV Pulmonary Lymphoepithelioma-Like Cancer With Pseudoprogression After Immunotherapy and Radiation

Patient Info: Anonymized, female, Under 40 | Stage IV

Biomarkers: EBER positive; no EGFR, ROS1, RAS/RAF or PIK3CA mutations/fusions detected

Through May 2025, follow-up showed no clear evidence of cancer recurrence or metastasis, with progression-free survival exceeding 70 months.

PubMed CentralRead more →

Stage IVB SMARCA4-deficient NSCLC with brain metastasis: stable disease after surgery, radiation, chemotherapy, immunotherapy, and bevacizumab

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: SMARCA4/BRG-1 loss with TP53 and other mutations; TMB high; PD-L1 <1%; MSI-H not detected.

Metastatic Site: brain

As of October 2025, the patient had stable disease, no brain recurrence, a controlled left lower-lobe lung lesion, and manageable treatment toxicity while continuing bevacizumab plus pemetrexed maintenance.

PubMed CentralRead more →

Small Cell Lung Cancer After a Remote Chest Gunshot Injury

Patient Info: Anonymized, male

Three years after surgery, surveillance imaging showed no signs of recurrence and he described himself as doing well.

PubMed CentralRead more →

Stage IV Lung Cancer: Tina's Patient Story

Patient Info: Tina Powell, Female | Stage IV

As of November 2025, Tina was living with Stage IV lung cancer after 27 chemotherapy rounds over 3 years and was receiving an antibody-drug conjugate in a clinical trial.

YouTube (AR search)Read more →

Stage IA2 lung adenocarcinoma followed by benign necrotizing sarcoid granulomatosis mimicking recurrence

Patient Info: Anonymized, Male, 60s

Postoperative enlarging nodules suspicious for recurrence were resected and diagnosed as necrotizing sarcoid granulomatosis, so observation continued without glucocorticoid therapy.

PubMed CentralRead more →

Stage IV Lung Cancer: Ross's Patient Story

Patient Info: Ross Camidge, Male | Stage IV

Biomarkers: Specific mutation identified; mutation name not reported

Metastatic Site: contralateral lung; mediastinal lymph nodes; bones

After a 2022 Stage IV diagnosis, Dr. Camidge was living with metastatic lung cancer between scans and continuing treatment; he described the disease as neither cured nor actively dying.

The Patient StoryRead more →